RT Journal Article
T1 Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer.
A1 Minicozzi, Pamela
A1 Van Eycken, Liesbet
A1 Molinie, Florence
A1 Innos, Kaire
A1 Guevara, Marcela
A1 Marcos-Gragera, Rafael
A1 Castro, Clara
A1 Rapiti, Elisabetta
A1 Katalinic, Alexander
A1 Torrella, Ana
A1 Žagar, Tina
A1 Bielska-Lasota, Magdalena
A1 Giorgi Rossi, Paolo
A1 Larrañaga, Nerea
A1 Bastos, Joana
A1 Sanchez-Perez, Maria-Jose
A1 Sant, Milena
K1 comorbidities
K1 early breast cancer
K1 outcomes
K1 population study
K1 standard treatment
AB Survival for breast cancer (BC) is lower in eastern than northern/central Europe, and in older than younger women. We analysed how comorbidities at diagnosis affected whether selected standard treatments (STs) were given, across Europe and over time, also assessing consequences for survival/relapse. We analysed 7581 stage I/IIA cases diagnosed in 9 European countries in 2009-2013, and 4 STs: surgery; breast-conserving surgery plus radiotherapy (BCS + RT); reconstruction after mastectomy; and prompt treatment (≤6 weeks after diagnosis). Covariate-adjusted models estimated odds of receiving STs and risks of death/relapse, according to comorbidities. Pearson's R assessed correlations between odds and risks. The z-test assessed the significance of time-trends. Most women received surgery: 72% BCS; 24% mastectomy. Mastectomied patients were older with more comorbidities than BCS patients (p
PB John Wiley & Sons, Inc.
YR 2018
FD 2018-10-23
LK http://hdl.handle.net/10668/13164
UL http://hdl.handle.net/10668/13164
LA en
NO Minicozzi P, Van Eycken L, Molinie F, Innos K, Guevara M, Marcos-Gragera R, et al. Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer. Int J Cancer. 2019 May 1;144(9):2118-2127.
NO The authors thank Don Ward for help with the English, and the participating cancer registries for collecting and preparing the data as part of their essential role in cancer control. This work was carried out as part of HIGHCARE (High resolution project on prognosis and care of cancer patients); it was supported in part by ERA-NET within the framework of the call on “Translational research on tertiary prevention in cancer patients” (TRANSCAN) with funding from: Ministry of Health, Italy; Research Foundation Flanders (FWO), Belgium; Institut National du Cancer, France; Federal Ministry of Education and Research (BMBF), Germany; Naradowe Centrum Badań i Rozwoju, Poland; Ministry of Education, Science and Sport (MIZS), Slovenia; and Instituto de Salud Carlos III, Spain. La Caixa Foundation partially supported the Navarra CR for this study. The Spanish National Institute of Health, Carlos III [grant number AC14/00036], and the Andalusian Department of Health [grant number PI-0152/2017] partially supported the Granada CR for this study.
DS RISalud
RD Apr 10, 2025